Manila Times Business
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026 NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex” or the "Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psyched
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The ChariTree Foundation Calls for More Outdoor Learning Opportunities for Children in the Age of AI
Just now
Budweiser China Co-Hosts Global Night-Time Economy Dialogue in Shanghai, Highlighting Multinational Companies’ Role in Urban Consumption Growth
Just now
Completion of the Sale of the Share of Saare Kala Tootmine OÜ
Just now
Shufti Ranked as a Leader in G2’s Summer 2026 Identity Verification Grid® Report
Just now